## §SELF — miscsubjects portable reference **Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next. **This widget:** `article_bundle` — **LLM article bundle** Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. - **article slug:** `tesamorelin-neuropathy` - **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest - **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system. - **read:** https://miscsubjects.com/api/articles/tesamorelin-neuropathy/bundle?format=markdown ### Logical proof (verify each step) 1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution 2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tesamorelin-neuropathy/sources 3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol 4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow 5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex 6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map ### Related features (explains other parts of the system) - **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/tesamorelin-neuropathy/topology - **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/tesamorelin-neuropathy/voxels - **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/tesamorelin-neuropathy/prompts - **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node. - **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/tesamorelin-neuropathy/voxels - **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest ### Full index - JSON: https://miscsubjects.com/api/articles/system-map - Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown ### §STRUCTURE This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure ### §INTEGRITY Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you. ### §GAUNTLET Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted. *Not medical advice. Tier-honest. Cite claim/source ids.* --- # miscsubjects article bundle > Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest. ## MASTHEAD - **identity:** `tesamorelin-neuropathy` v2 · content_hash `7edceba6c8f8c500…` · thread_head genesis · 22 DIVs - **thesis (c1):** An ongoing Phase 2 RCT (NCT03150511) is testing tesamorelin for functional recovery after peripheral nerve injury with no published results yet. - c3 [human/active] Tesamorelin reduces visceral fat and increases IGF-1 in multiple human RCTs for HIV lipodystrophy. - c4 [human/active] Paresthesia and peripheral neuropathy are listed among nervous system adverse events in tesamorelin prescribing information. - c2 [preclinical/active] Animal studies show growth hormone improves nerve regeneration and functional recovery after injury. - **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes - **standing objections:** 0 open → https://miscsubjects.com/api/articles/tesamorelin-neuropathy/discourse - **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key - **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/tesamorelin-neuropathy/discourse · https://miscsubjects.com/api/protocol ## Article - **slug:** `tesamorelin-neuropathy` - **title:** Tesamorelin for Neuropathy: Evidence-Graded Review - **url:** https://miscsubjects.com/a/tesamorelin-neuropathy - **register:** source_ledger - **updated:** 2026-07-17T02:42:24.485Z - **tags:** peptide, matrix ## Body ## What's breaking down Neuropathy involves degeneration of peripheral nerves. Axons may be damaged or severed after injury or disease. Myelin sheaths can degrade. Schwann cells struggle to support regrowth. Blood flow to nerves may drop. Inflammation can persist. Over time, motor and sensory function decline because repair pathways lag behind ongoing breakdown. ## Why Tesamorelin might help you Tesamorelin stimulates the growth hormone axis. It raises GH and IGF-1 levels. If your neuropathy involves impaired axonal regeneration or muscle atrophy after nerve injury, this pathway is discussed for potential tissue repair support. 1. Therefore for you: If axonal regrowth is a limiting factor, Tesamorelin is studied because GH/IGF-1 signaling has been linked in animal models to faster nerve fiber extension. 2. Therefore for you: If muscle wasting follows denervation, the same axis may help preserve or rebuild muscle tissue indirectly. 3. Therefore for you: If visceral fat or metabolic stress adds to nerve load, Tesamorelin's documented effect on reducing abdominal fat could ease secondary strain, though this remains separate from direct nerve effects. 4. Therefore for you: Tesamorelin targets repair signaling rather than symptom masking. ## How these fit together Single-compound focus. Tesamorelin addresses the GH axis and visceral fat layer. No sibling peptides are in scope here. ## What the evidence actually shows Human data: One ongoing Phase 2 randomized, double-blind, placebo-controlled trial (NCT03150511) is testing tesamorelin after peripheral nerve injury repair. The trial enrolls patients with ulnar nerve lacerations. It measures motor and sensory recovery over one year. As of 2026 the study remains active with no published efficacy results. Preclinical data: Animal studies indicate growth hormone improves nerve regeneration and functional recovery after injury. These findings form the rationale for the human trial. Human safety data from lipodystrophy trials: Tesamorelin reliably lowers visceral adipose tissue and raises IGF-1. Side effects include injection-site reactions, arthralgia, and paresthesia. Some reports list peripheral neuropathy as a possible adverse event. Tier summary: No completed human efficacy trials for neuropathy exist. All neuropathy benefit claims sit at preclinical or mechanistic tier. ## What scientists say Researchers at Johns Hopkins hypothesize that tesamorelin will speed axonal regeneration via elevated growth hormone. The trial protocol states growth hormone has improved nerve outcomes in animal models. No peer-reviewed conclusions on human neuropathy patients are available yet. ## What people say on Reddit Users discuss the ongoing nerve-injury trial. One post notes the study is examining whether tesamorelin helps axons regrow. No personal reports of using tesamorelin specifically for neuropathy symptoms appear in recent threads. General peptide discussions focus on fat loss or side effects such as joint discomfort. ## What people say on X Limited public posts. Mentions center on the clinical trial announcement or general GH peptide interest. No detailed patient anecdotes on neuropathy resolution. ## What we do not know Whether tesamorelin improves nerve function, sensation, or pain in humans with neuropathy. Optimal timing after injury. Effects in diabetic or chemotherapy-induced neuropathy. Long-term nerve-specific outcomes. Interaction with other neuropathy treatments. ## Safety and limits Tesamorelin is FDA-approved only for HIV-related visceral fat. It carries risks of fluid retention, joint pain, and glucose changes. Carpal tunnel symptoms and paresthesia have occurred. Active cancer or pituitary disorders are contraindications in approved use. Neuropathy application remains investigational only. ## Claims (4) - **c4** [human w=0.8] Paresthesia and peripheral neuropathy are listed among nervous system adverse events in tesamorelin prescribing information. - who_claims: grok/grok-4.3 - slot: limitations - sources: s4 - **c2** [preclinical w=0.5] Animal studies show growth hormone improves nerve regeneration and functional recovery after injury. - who_claims: grok/grok-4.3 - sources: s2 - **c1** [human w=0.8] An ongoing Phase 2 RCT (NCT03150511) is testing tesamorelin for functional recovery after peripheral nerve injury with no published results yet. - who_claims: grok/grok-4.3 - sources: s1 - **c3** [human w=0.8] Tesamorelin reduces visceral fat and increases IGF-1 in multiple human RCTs for HIV lipodystrophy. - who_claims: grok/grok-4.3 - sources: s3 ## Voxel graph (4 atoms · 8 edges) - full graph: https://miscsubjects.com/api/articles/tesamorelin-neuropathy/voxels ## Article constitution - full: https://miscsubjects.com/api/articles/constitution ## Source ledger (4) - chain valid: yes · head: `2f341cfc8d9e768a` ### s1 · clinical_trial · ok - title: Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury - url: https://clinicaltrials.gov/study/NCT03150511 - summary: Active Phase 2 trial protocol details; no results posted. - quote: The aim of this clinical trial is to evaluate the efficacy of tesamorelin as a therapy for peripheral nerve injuries. - claim_ids: c1 - hash: `fcca5072d1948172` ### s2 · medical · ok - title: Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury - url: https://www.centerwatch.com/clinical-trials/listings/NCT03150511/tesamorelin-to-improve-functional-outcomes-after-peripheral-nerve-injury - summary: Trial background cites preclinical GH nerve data. - quote: growth hormone has been shown to improve nerve regeneration and functional recovery in animal studies. - claim_ids: c2 - hash: `ef5b229c2a720684` ### s3 · pubmed · ok - title: Effects of tesamorelin... in HIV-infected patients with abdominal fat accumulation - url: https://pubmed.ncbi.nlm.nih.gov/20101189/ - summary: Pooled Phase 3 data on VAT reduction and IGF-1 increase. - quote: Tesamorelin reduces visceral fat by approximately 18 % - claim_ids: c3 - hash: `8f6e93d9e5b2301f` ### s4 · medical · http_403 - title: Tesamorelin Side Effects - url: https://www.drugs.com/sfx/tesamorelin-side-effects.html - summary: Lists neuropathy-related adverse events from approved use. - quote: Common (1% to 10%): ... peripheral neuropathy - claim_ids: c4 - hash: `2f341cfc8d9e768a` ## Provenance (2 model passes) - chain valid: yes · head: `c254bcb023a5c4bd` - write · grok/grok-4.3 · 2026-06-29T23:18 · hash `680aa8d69383` - voxel_divide · owner · 2026-07-17T02:42 · hash `c254bcb023a5` ## Question graph - questions: 0 · evidence ingests: 0 ## LLM manifest — how to communicate with this ledger - system map: https://miscsubjects.com/api/articles/system-map?format=markdown - topology (ranked): https://miscsubjects.com/api/articles/tesamorelin-neuropathy/topology - ingest: POST https://miscsubjects.com/api/protocol/ingest - claim: POST https://miscsubjects.com/api/protocol/claim ### Quick actions for this article - **Read live:** https://miscsubjects.com/api/articles/tesamorelin-neuropathy/topology - **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"tesamorelin-neuropathy","question":"..."}` - **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest tesamorelin-neuropathy|your evidence` - **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim tesamorelin-neuropathy|tier|assertion` - **iMessage ask:** `tesamorelin-neuropathy|your question` - **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown --- ## §SELF — miscsubjects portable reference **Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next. **This widget:** `system_map` — **System map** Root index of every miscsubjects article-ledger feature. Start here if you have zero context. - **article slug:** `tesamorelin-neuropathy` - **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest - **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context. - **read:** https://miscsubjects.com/api/articles/system-map ### Logical proof (verify each step) 1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution 2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tesamorelin-neuropathy/sources 3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol 4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow 5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex 6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map ### Related features (explains other parts of the system) - **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution - **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest - **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip - **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip - **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/tesamorelin-neuropathy/bundle?format=markdown - **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown ### Full index - JSON: https://miscsubjects.com/api/articles/system-map - Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown ### §STRUCTURE This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure ### §INTEGRITY Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you. ### §GAUNTLET Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted. *Not medical advice. Tier-honest. Cite claim/source ids.*